Symposium 4
State-of-the-art Preoperative Chemoradiotherapy for Pancreatic Surgery

[SY4-2] Phase 2 trial of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer: Results of JASPAC05

^○Soichiro Morinaga¹, Shinichiro Takahashi², Masafumi Ikeda³, Hirochika Toyama⁴, Yasuhiro Shimizu⁵, Shoji Nakamori⁶, Shoichi Hishinuma⁷, Norihisa Takakura⁸, Wataru Takayama⁹, Satoshi Hirano¹⁰, Takehito Otsubo¹¹, Masato Nagino¹², Wataru Kimura¹³, Keishi Sugimachi¹⁴, Katsuhiko Uesaka¹⁵ (1.Department of Gastroenterological Surgery, Kanagawa Cancer Center, Yokohama, Japan, 2.Department of Hepato-Biliary-Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan, 3.Department of Hepato-Biliary-Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 4.Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 5.Department of Hepato-Biliary-Pancreatic Surgery, Aichi Cancer Center, Nagoya, Japan, 6.National Hospital Organization Osaka National Hospital, Dept. of Hepato-Biliary-Pancreatic Surgery, 7.Tochigi Cancer Center, Dept. of Hepato-Biliary-Pancreatic Surgery, 8.Fukuyama City Hospital, Dept. of Surgery, 9.Chiba Cancer Center, Dept. of Hepato-Biliary-Pancreatic Surgery, 10.Hokkaido University Hospital, Dept. of Gastroenterological Surgery II, 11.St. Marianna University School of Medicine Hospital, Dept. of Gastroenterological Surgery, 12.Nagoya University Hospital, Gastroenterological Surgery 1, 13.Yamagata University Hospital, Dept. of Surgery 1, 14.National Hospital Organization Kyusyu Cancer Center, 15.Shizuoka Cancer Center, Dept. of Hepato-Biliary-Pancreatic Surgery)